$PBIO
PRESSURE BIOSCIENCES INC Stock $pbio

$pbio Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000149315223017552 Filed on May 15, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$512.0K	$740.6K	$480.0K
YoY Change	2.78%	54.29%	-14.27%
Cost Of Revenue	$256.6K	$358.6K	$314.4K
YoY Change	-15.07%	14.08%	38.93%
Gross Profit	$255.4K	$382.0K	$165.6K
YoY Change	30.31%	130.6%	-50.35%
Gross Profit Margin	49.88%	51.58%	34.51%
Selling, General & Admin	$1.056M	$3.584M	$970.4K
YoY Change	14.2%	269.36%	-12.48%
% of Gross Profit	413.58%	938.31%	585.82%
Research & Development	$280.4K	$435.6K	$281.6K
YoY Change	62.36%	54.71%	-6.12%
% of Gross Profit	109.81%	114.05%	170.0%
Depreciation & Amortization	$28.12K	$28.11K	$35.10K
YoY Change	3.73%	-19.91%	29.09%
% of Gross Profit	11.01%	7.36%	21.19%
Operating Expenses	$1.337M	$4.020M	$1.252M
YoY Change	21.78%	221.08%	-11.13%
Operating Profit	-$1.082M	-$3.638M	-$1.086M
YoY Change	19.95%	234.87%	1.04%
Interest Expense	$5.880M	$3.894M	-$2.560M
YoY Change	220.31%	-252.1%	-46.4%
% of Operating Profit
Other Income/Expense, Net	-$5.841M	-$3.220M	-$3.510K
YoY Change	189.93%	91640.43%	158.09%
Pretax Income	-$6.923M	-$6.858M	-$4.240M
YoY Change	137.38%	61.75%	-35.54%
Income Tax
% Of Pretax Income
Net Earnings	-$6.923M	-$6.858M	-$4.240M
YoY Change	137.38%	61.75%	-35.54%
Net Earnings / Revenue	-1352.09%	-925.98%	-883.27%
Basic Earnings Per Share	-$0.57	-$0.46	-$0.48
Diluted Earnings Per Share	-$0.57	-$0.46	-$437.3K
COMMON SHARES
Basic Shares Outstanding	16.77M shares	15.87M shares	9.695M shares
Diluted Shares Outstanding	19.47M shares	15.84M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$24.98K	$239.0K	$118.8K
YoY Change	-79.45%	101.2%	135.11%
Cash & Equivalents	$24.98K	$239.0K	$118.8K
Short-Term Investments
Other Short-Term Assets	$281.0K	$257.6K	$184.9K
YoY Change	23.12%	39.26%	-31.92%
Inventory	$553.7K	$666.0K	$1.361M
Prepaid Expenses
Receivables	$189.0K	$392.2K	$291.9K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.049M	$1.555M	$1.956M
YoY Change	-48.14%	-20.52%	41.13%
LONG-TERM ASSETS
Property, Plant & Equipment	$93.39K	$99.87K	$472.5K
YoY Change	-8.26%	-78.86%	114.06%
Goodwill
YoY Change
Intangibles	$274.0K	$295.7K
YoY Change	-24.0%
Long-Term Investments	$83.88K	$71.70K	$79.11K
YoY Change	38.41%	-9.37%	-80.66%
Other Assets
YoY Change
Total Long-Term Assets	$627.1K	$659.1K	$933.9K
YoY Change	-27.48%	-29.43%	-15.0%
TOTAL ASSETS
Total Short-Term Assets	$1.049M	$1.555M	$1.956M
Total Long-Term Assets	$627.1K	$659.1K	$933.9K
Total Assets	$1.676M	$2.214M	$2.890M
YoY Change	-41.95%	-23.4%	16.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$912.2K	$769.0K	$665.2K
YoY Change	65.05%	15.59%	-6.48%
Accrued Expenses	$2.914M	$2.788M	$2.439M
YoY Change	15.03%	14.27%	-7.74%
Deferred Revenue
YoY Change
Short-Term Debt	$19.10M	$19.56M	$15.80M
YoY Change	8.55%	23.81%	38.01%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$26.54M	$34.40M	$27.25M
YoY Change	-10.78%	26.23%	22.02%
LONG-TERM LIABILITIES
Long-Term Debt	$163.2K	$163.8K	$150.0K
YoY Change	8.79%	9.23%	-71.54%
Other Long-Term Liabilities	$86.81K	$97.20K	$235.8K
YoY Change	-57.23%	-58.78%	56.06%
Total Long-Term Liabilities	$250.0K	$261.0K	$385.8K
YoY Change	-29.18%	-32.34%	-43.11%
TOTAL LIABILITIES
Total Short-Term Liabilities	$26.54M	$34.40M	$27.25M
Total Long-Term Liabilities	$250.0K	$261.0K	$385.8K
Total Liabilities	$26.79M	$34.66M	$27.64M
YoY Change	-10.99%	25.42%	20.1%
SHAREHOLDERS EQUITY
Retained Earnings	-$152.2M	-$141.1M
YoY Change	22.73%
Common Stock	$195.9K	$180.6K
YoY Change	82.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$25.12M	-$32.45M	-$24.75M
YoY Change
Total Liabilities & Shareholders Equity	$1.676M	$2.214M	$2.890M
YoY Change	-41.95%	-23.4%	16.31%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$6.923M	-$6.858M	-$4.240M
YoY Change	137.38%	61.75%	-35.54%
Depreciation, Depletion And Amortization	$28.12K	$28.11K	$35.10K
YoY Change	3.73%	-19.91%	29.09%
Cash From Operating Activities	-$899.2K	-$422.2K	-$756.3K
YoY Change	-27.6%	-44.17%	-38.86%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$3.000K	-$1.140K
YoY Change	-100.0%	-363.16%	-71.21%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	-$3.000K	-$1.140K
YoY Change	-100.0%	163.16%	-71.21%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	685.1K	$660.4K	743.9K
YoY Change	-45.12%	-11.23%	-41.56%
NET CHANGE
Cash From Operating Activities	-899.2K	-$422.2K	-756.3K
Cash From Investing Activities	0.000	-$3.000K	-1.140K
Cash From Financing Activities	685.1K	$660.4K	743.9K
Net Change In Cash	-214.1K	$235.2K	-13.51K
YoY Change	-7827.44%	-1840.62%	-142.23%
FREE CASH FLOW
Cash From Operating Activities	-$899.2K	-$422.2K	-$756.3K
Capital Expenditures	$0.00	$3.000K	-$1.140K
Free Cash Flow	-$899.2K	-$425.2K	-$755.1K
YoY Change	-27.38%	-43.69%	-38.76%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000830656
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	PBIO	Loss On Extinguishment Of Accrued Liabilities And Debt LossOnExtinguishmentOfAccruedLiabilitiesAndDebt		usd
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2022Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
CY2023Q1	PBIO	Early Asu202006 Adoption EarlyAsu202006Adoption		usd
CY2023Q1	PBIO	Discount From Warrants Issued With Debt DiscountFromWarrantsIssuedWithDebt		usd
CY2022Q1	PBIO	Conversion Of Preferred Stock For Common Stock ConversionOfPreferredStockForCommonStock		usd
CY2023Q1	PBIO	Stock Issued During Period Value Conversion Of Convertible Securities Conversion Of Preferred Stock For Common Stock StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConversionOfPreferredStockForCommonStock		usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour		usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-38185
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	PRESSURE BIOSCIENCES, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	MA
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-2652826
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	14 Norfolk Avenue
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	South Easton
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02375
CY2023Q1	dei	City Area Code CityAreaCode	(508)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	230-1828
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16772761	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	239023	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3865	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	392154	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	295374	usd
CY2023Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	982973	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	982973	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	666045	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	686383	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	257552	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	257527	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	1554774	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1243149	usd
CY2023Q1	us-gaap	Equity Method Investments EquityMethodInvestments	71699	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	63638	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	99872	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	103351	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	191816	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	282095	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	295673	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	317308	usd
CY2023Q1	us-gaap	Assets Assets	2213834	usd
CY2022Q4	us-gaap	Assets Assets	2009541	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	768967	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	637238	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	268546	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	167247	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2453995	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2497762	usd
CY2023Q1	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	10811069	usd
CY2022Q4	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	10803983	usd
CY2023Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	475987	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	58242	usd
CY2023Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	17741416	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	17823669	usd
CY2023Q1	PBIO	Other Debt Unamortized Discounts Net OtherDebtUnamortizedDiscountsNet	485672	usd
CY2022Q4	PBIO	Other Debt Unamortized Discounts Net OtherDebtUnamortizedDiscountsNet	0	usd
CY2023Q1	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	1185028	usd
CY2022Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	1638969	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	632085	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	634885	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	65029	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	142171	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	34402122	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	34404166	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	163838	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	150000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	90052	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	139924	usd
CY2023Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	7143	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1822	usd
CY2023Q1	us-gaap	Liabilities Liabilities	34663155	usd
CY2022Q4	us-gaap	Liabilities Liabilities	34695912	usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	86	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	1098	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18064240	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18064240	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13682910	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13682910	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	180643	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	136829	usd
CY2023Q1	PBIO	Warrants To Acquire Common Stock WarrantsToAcquireCommonStock	32057371	usd
CY2022Q4	PBIO	Warrants To Acquire Common Stock WarrantsToAcquireCommonStock	31995762	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	76428425	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	69006145	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-141115846	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-133826205	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-32449321	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-32686371	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2213834	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2009541	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	740600	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	480000	usd
CY2023Q1	us-gaap	Revenues Revenues	740600	usd
CY2022Q1	us-gaap	Revenues Revenues	480000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	358628	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	314363	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	435646	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	281589	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	226015	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	66462	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3358056	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	903885	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	4378345	usd
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	1566299	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3637745	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1086299	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	3893686	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	2579161	usd
CY2023Q1	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	8061	usd
CY2022Q1	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	19138	usd
CY2023Q1	PBIO	Loss On Extinguishment Of Liabilities LossOnExtinguishmentOfLiabilities	659277	usd
CY2022Q1	PBIO	Loss On Extinguishment Of Liabilities LossOnExtinguishmentOfLiabilities	-589850	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6259	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3513	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3220089	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3153386	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-6857834	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4239685	usd
CY2023Q1	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	431807	usd
CY2022Q1	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	432149	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7289641	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4671834	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15839373	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9695189	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-6857834	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4239685	usd
CY2023Q1	PBIO	Gains On Extinguishment Of Debt GainsOnExtinguishmentOfDebt	659277	usd
CY2022Q1	PBIO	Gains On Extinguishment Of Debt GainsOnExtinguishmentOfDebt	10000	usd
CY2023Q1	PBIO	Noncash Lease Expense NoncashLeaseExpense	90279	usd
CY2022Q1	PBIO	Noncash Lease Expense NoncashLeaseExpense	26559	usd
CY2023Q1	PBIO	Common Stock And Warrants Issued For Interest CommonStockAndWarrantsIssuedForInterest	1705234	usd
CY2022Q1	PBIO	Common Stock And Warrants Issued For Interest CommonStockAndWarrantsIssuedForInterest	1173458	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	28114	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	35096	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-615007	usd
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-817877	usd
CY2022Q1	PBIO	Loss On Extinguishment Of Accrued Liabilities And Debt LossOnExtinguishmentOfAccruedLiabilitiesAndDebt	589570	usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1029939	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1430244	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	64483	usd
CY2023Q1	us-gaap	Debt And Equity Securities Realized Gain Loss DebtAndEquitySecuritiesRealizedGainLoss	8061	usd
CY2022Q1	us-gaap	Debt And Equity Securities Realized Gain Loss DebtAndEquitySecuritiesRealizedGainLoss	19138	usd
CY2023Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1480944	usd
CY2022Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	117461	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	96780	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	137100	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-20338	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	212985	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	25	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-237681	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	131729	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	137304	usd
CY2023Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	101299	usd
CY2022Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	52532	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-127014	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-26559	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	693653	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	637164	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-422211	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-756282	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1135	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1135	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	100000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	81111	usd
CY2023Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	2520000	usd
CY2022Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	806000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	654681	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	351150	usd
CY2023Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	88200	usd
CY2022Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	195250	usd
CY2023Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1628474	usd
CY2022Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	324350	usd
CY2023Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	99000	usd
CY2023Q1	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	1056149	usd
CY2022Q1	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	284141	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	660369	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	743909	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	235158	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-13508	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3865	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	132311	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	239023	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	118803	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	534872	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	120436	usd
CY2022Q1	PBIO	Early Asu202006 Adoption EarlyAsu202006Adoption	473027	usd
CY2023Q1	us-gaap	Stock Issued1 StockIssued1	1087751	usd
CY2022Q1	us-gaap	Stock Issued1 StockIssued1	142480	usd
CY2022Q1	PBIO	Discount From Warrants Issued With Debt DiscountFromWarrantsIssuedWithDebt	87436	usd
CY2023Q1	PBIO	Common Stock Issued In Lieu Of Cash For Dividend CommonStockIssuedInLieuOfCashForDividend	102435	usd
CY2022Q1	PBIO	Common Stock Issued In Lieu Of Cash For Dividend CommonStockIssuedInLieuOfCashForDividend	64256	usd
CY2023Q1	PBIO	Noncash Preferred Stock Dividends NoncashPreferredStockDividends	431807	usd
CY2022Q1	PBIO	Noncash Preferred Stock Dividends NoncashPreferredStockDividends	432149	usd
CY2023Q1	PBIO	Conversion Of Preferred Stock For Common Stock ConversionOfPreferredStockForCommonStock	4935	usd
CY2023Q1	PBIO	Conversion Of Debt Into Common Stock ConversionOfDebtIntoCommonStock	509033	usd
CY2022Q1	PBIO	Conversion Of Debt Into Common Stock ConversionOfDebtIntoCommonStock	350500	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-22208961	usd
CY2022Q1	PBIO	Cumulative Effect Period Of Adoption Adjustment CumulativeEffectPeriodOfAdoptionAdjustment	-473027	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	64483	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	432149	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	77700	usd
CY2022Q1	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	39761	usd
CY2022Q1	PBIO	Warrants Issued For Debt Extension WarrantsIssuedForDebtExtension	132537	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	472900	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	350500	usd
CY2022Q1	PBIO	Issuance Of Common Stock For Dividends Paidinkind IssuanceOfCommonStockForDividendsPaidinkind	64256	usd
CY2022Q1	PBIO	Issuance Of Common Stock For Interest Paidinkind IssuanceOfCommonStockForInterestPaidinkind	1173458	usd
CY2022Q1	PBIO	Stock Issued With Debt StockIssuedWithDebt	142480	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	87436	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4239685	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-24748311	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-32686371	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	81111	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1430244	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	431807	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1419335	usd
CY2023Q1	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	61609	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	509033	usd
CY2023Q1	PBIO	Issuance Of Common Stock For Dividends Paidinkind IssuanceOfCommonStockForDividendsPaidinkind	102435	usd
CY2023Q1	PBIO	Issuance Of Common Stock For Interest Paidinkind IssuanceOfCommonStockForInterestPaidinkind	1705234	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1029939	usd
CY2023Q1	PBIO	Stock Issued With Debt StockIssuedWithDebt	1087751	usd
CY2023Q1	PBIO	Sale Of Common Stock For Cash SaleOfCommonStockForCash	100000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-6857834	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-32449321	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_840_eus-gaap--UseOfEstimates_zmBX6VEKaeia" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zpLUsnGwJHxi">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s consolidated financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America, which require the use of estimates, judgements and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented. Global concerns about the COVID-19 pandemic have adversely affected, and we expect will continue to adversely affect, our business, financial condition and results of operations including the estimates and assumptions made by management. Significant estimates and assumptions include valuations of share-based awards, investments in equity securities and intangible asset impairment. Actual results could differ from the estimates, and such differences may be material to the Company’s consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2020Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2728243	usd
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	2255216	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	741000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	480000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	741000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	480000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	741000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	480000	usd
CY2023Q1	us-gaap	Accounts Receivable Billed For Long Term Contracts Or Programs AccountsReceivableBilledForLongTermContractsOrPrograms	392000	usd
CY2022Q4	us-gaap	Accounts Receivable Billed For Long Term Contracts Or Programs AccountsReceivableBilledForLongTermContractsOrPrograms	295000	usd
CY2023Q1	us-gaap	Deferred Revenue DeferredRevenue	483000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	60000	usd
CY2023Q1	PBIO	Extended Warranty Service ExtendedWarrantyService	65000	usd
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84E_eus-gaap--ConcentrationRiskCreditRisk_z6x9vgwp1mhc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_z1ynmyEHP7h9">Concentrations</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Credit Risk</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions, large pharmaceutical and biotechnology companies, and academic laboratories.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--FairValueConcentrationOfRiskTextBlock_zDpkuZIhMbyh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table illustrates the level of concentration as a percentage of total revenues during the three months ended March 31, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B3_z21QrO0Rux7e" style="display: none">Schedule of Customer Concentration Risk Percentage</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="6" style="text-align: center">For the Three Months Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Top Five Customers</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zMRjk5gXRkm3" style="width: 20%; text-align: right" title="Concentration credit risk percentage">64</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z71krVwStRod" style="width: 20%; text-align: right" title="Concentration credit risk percentage">73</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Federal Agencies</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zqcMyTwvKyY5" style="text-align: right" title="Concentration credit risk percentage">1</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z9C7jdP65o25" style="text-align: right" title="Concentration credit risk percentage">0</td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of March 31, 2023 and December 31, 2022. The Top Five Customers category may include federal agency receivable balances if applicable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: justify">Top Five Customers</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zIzfjupewK4b" style="width: 20%; text-align: right" title="Concentration credit risk percentage">92</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zdFKTlVMk9Lh" style="width: 20%; text-align: right" title="Concentration credit risk percentage">93</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Federal Agencies</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zNSJa4SHTDo2" style="text-align: right" title="Concentration credit risk percentage">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zfdW6axyfJ3f" style="text-align: right" title="Concentration credit risk percentage">0</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A5_zKMU3ePYb8i9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7289641	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4671834	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15839373	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9695189	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	35909806	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	32475868	shares
CY2023Q1	PBIO	Forfeiture Rate ForfeitureRate	0.05	pure
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1430244	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	64483	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1430244	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	64483	usd
CY2023Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	71699	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	63638	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	149300	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	64393	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	66969	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	51777	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	332439	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	177358	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	155081	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	90279	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	26559	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y10M2D
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	191816	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	282095	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	65029	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	142171	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	90052	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	139924	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	155081	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	282095	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2023Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	0	usd
CY2022Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	0	usd
CY2023Q1	us-gaap	Debt Conversion Original Debt Interest Rate Of Debt DebtConversionOriginalDebtInterestRateOfDebt	0.35	pure
CY2023Q1	PBIO	Convertible Lesser Per Share ConvertibleLesserPerShare	2.50
CY2023Q1	PBIO	Convertible Lesser Discount Percent ConvertibleLesserDiscountPercent	0.25	pure
CY2023Q1	us-gaap	Debt Instrument Convertible Threshold Trading Days DebtInstrumentConvertibleThresholdTradingDays	5	integer
CY2023Q1	us-gaap	Other Long Term Debt OtherLongTermDebt	1834538	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	37810	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	37810	usd
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	20850	usd
CY2022Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	20850	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	58660	usd
CY2022Q1	us-gaap	Lease Cost LeaseCost	58660	usd
CY2023Q1	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	535250	usd
CY2023Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1628474	usd
CY2023Q1	us-gaap	Debt Instrument Maturity Date Description DebtInstrumentMaturityDateDescription	July, 2020 to March, 2024
CY2023Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	14000000	usd
CY2023Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	19414704	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	18279186	usd
CY2023Q1	PBIO	Debt Discount DebtDiscount	1673288	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	455517	usd
CY2023Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	17741416	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	17823669	usd
CY2023Q1	us-gaap	Debt Instrument Convertible Stock Price Trigger DebtInstrumentConvertibleStockPriceTrigger	2.50
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2023Q1	PBIO	Debt Default Convertible Conversion Ratio DebtDefaultConvertibleConversionRatio	0.75	pure
CY2023Q1	us-gaap	Debt Instrument Convertible Stock Price Trigger DebtInstrumentConvertibleStockPriceTrigger	2.50
CY2023Q1	PBIO	Debt Default Convertible Conversion Ratio DebtDefaultConvertibleConversionRatio	0.75	pure
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price Increase DebtInstrumentConvertibleConversionPriceIncrease	2.50
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price Increase DebtInstrumentConvertibleConversionPriceIncrease	2.50
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price Decrease DebtInstrumentConvertibleConversionPriceDecrease	2.50
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price Increase DebtInstrumentConvertibleConversionPriceIncrease	2.50
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2023Q1	us-gaap	Debt Default Longterm Debt Amount DebtDefaultLongtermDebtAmount	1	usd
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2023Q1	PBIO	Percentage Of Price Rate PercentageOfPriceRate	0.10	pure
CY2023Q1	PBIO	Convertible Lesser Per Share ConvertibleLesserPerShare	2.5
CY2023Q1	PBIO	Convertible Lesser Discount Percent ConvertibleLesserDiscountPercent	0.25	pure
CY2022Q4	us-gaap	Other Long Term Debt OtherLongTermDebt	1788969	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	485672	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	163838	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	150000	usd
CY2023Q1	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	1185028	usd
CY2022Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	1638969	usd
CY2023Q1	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2023-05-02
CY2023Q1	PBIO	Non Convertible Debt Instrument Amount NonConvertibleDebtInstrumentAmount	866308	usd
CY2023Q1	us-gaap	Notes Payable NotesPayable	150000	usd
CY2023Q1	PBIO	Accrued Interest Rate Percent AccruedInterestRatePercent	0.0375	pure
CY2023Q1	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	731	usd
CY2023Q1	PBIO	Deferred Interest DeferredInterest	14719	usd
CY2023Q1	us-gaap	Principal Transactions Revenue PrincipalTransactionsRevenue	880	usd
CY2023Q1	us-gaap	Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue	86	usd
CY2022Q4	us-gaap	Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue	1098	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	17586591	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	17570591	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2330484	shares
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	117552	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	161668	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	19637855	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	18538573	shares

Files In Submission

Name	View Source	Status
0001493152-23-017552-index-headers.html	Edgar Link	pending
0001493152-23-017552-index.html	Edgar Link	pending
0001493152-23-017552.txt	Edgar Link	pending
0001493152-23-017552-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pbio-20230331.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
pbio-20230331_cal.xml	Edgar Link	unprocessable
pbio-20230331_def.xml	Edgar Link	unprocessable
pbio-20230331_lab.xml	Edgar Link	unprocessable
pbio-20230331_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PBIO
PRESSURE BIOSCIENCES INC Stock $pbio

2023 Q2 Form 10-Q Financial Statement

#000149315223017552 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBIO PRESSURE BIOSCIENCES INC Stock $pbio

2023 Q2 Form 10-Q Financial Statement

#000149315223017552 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBIO
PRESSURE BIOSCIENCES INC Stock $pbio